DMAC Valuation

DiaMedica Therapeutics Inc

Add to Watchlist

Advanced Chart

5.760

-0.27(-4.478%)1D

Overview
Forecast
Valuation
Earnings

DMAC Relative Valuation

DMAC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, DMAC is overvalued; if below, it's undervalued.

Historical Valuation

DiaMedica Therapeutics Inc (DMAC) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -5.02. The fair price of DiaMedica Therapeutics Inc (DMAC) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：5.76

Fair

-8.30

Trailing

Forward

-7.25

EV/EBITDA

DiaMedica Therapeutics Inc. (DMAC) has a current EV/EBITDA of -7.25. The 5-year average EV/EBITDA is -2.82. The thresholds are as follows: Strongly Undervalued below -7.92, Undervalued between -7.92 and -5.37, Fairly Valued between -0.27 and -5.37, Overvalued between -0.27 and 2.28, and Strongly Overvalued above 2.28. The current Forward EV/EBITDA of -7.25 falls within the Undervalued range.

-7.51

EV/EBIT

DiaMedica Therapeutics Inc. (DMAC) has a current EV/EBIT of -7.51. The 5-year average EV/EBIT is -2.92. The thresholds are as follows: Strongly Undervalued below -7.68, Undervalued between -7.68 and -5.30, Fairly Valued between -0.54 and -5.30, Overvalued between -0.54 and 1.85, and Strongly Overvalued above 1.85. The current Forward EV/EBIT of -7.51 falls within the Undervalued range.

0.00

DiaMedica Therapeutics Inc. (DMAC) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.

-9.14

P/OCF

DiaMedica Therapeutics Inc. (DMAC) has a current P/OCF of -9.14. The 5-year average P/OCF is -1.35. The thresholds are as follows: Strongly Undervalued below -7.75, Undervalued between -7.75 and -4.55, Fairly Valued between 1.85 and -4.55, Overvalued between 1.85 and 5.05, and Strongly Overvalued above 5.05. The current Forward P/OCF of -9.14 falls within the Strongly Undervalued range.

-9.14

P/FCF

DiaMedica Therapeutics Inc. (DMAC) has a current P/FCF of -9.14. The 5-year average P/FCF is -2.99. The thresholds are as follows: Strongly Undervalued below -11.06, Undervalued between -11.06 and -7.02, Fairly Valued between 1.05 and -7.02, Overvalued between 1.05 and 5.09, and Strongly Overvalued above 5.09. The current Forward P/FCF of -9.14 falls within the Undervalued range.

DiaMedica Therapeutics Inc (DMAC) has a current Price-to-Book (P/B) ratio of 9.56. Compared to its 3-year average P/B ratio of 2.76 , the current P/B ratio is approximately 245.77% higher. Relative to its 5-year average P/B ratio of 3.11, the current P/B ratio is about 207.74% higher. DiaMedica Therapeutics Inc (DMAC) has a Forward Free Cash Flow (FCF) yield of approximately -8.24%. Compared to its 3-year average FCF yield of -18.18%, the current FCF yield is approximately -54.67% lower. Relative to its 5-year average FCF yield of -16.16% , the current FCF yield is about -49.01% lower.

9.56

P/B

Median3y

2.76

Median5y

3.11

-8.24

FCF Yield

Median3y

-18.18

Median5y

-16.16

Competitors Valuation Multiple

The average P/S ratio for DMAC's competitors is 19077.15, providing a benchmark for relative valuation. DiaMedica Therapeutics Inc Corp (DMAC) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

DMAC.O

DiaMedica Therapeutics Inc

Loss

Average P/S: 19077.15

297.73M

DSGN.O

Design Therapeutics Inc

Aldeyra Therapeutics Inc

Performance Decomposition

Market capitalization of DMAC increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of DMAC in the past 1 year is driven by Unknown.